ReviewMolecules (Basel, Switzerland)2016
Phlorotannins: Towards New Pharmacological Interventions for Diabetes Mellitus Type 2.
Review in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 94 citations in OpenAlex.
- Marginal Impact of Brown SeaweedMarine drugs · 2022Trial
- Fucoidan and alginate from brown seaweeds: extraction, structural diversity, biocompatibility, biodegradability, and biomedical applications.Frontiers in plant science · 2026Review
- Seaweed phenolic compounds: Relationship with antioxidant activity and application in different food products.Food chemistry: X · 2025Review
- Mechanisms behind the anti-diabetic and anti-obesity effects of seaweeds or macroalgae and their bioactive compounds.World journal of diabetes · 2025Review
- Combined Metabolomics and Network Pharmacology to Reveal Anti-Diabetic Mechanisms and Potential Pharmacological Components ofPlants (Basel, Switzerland) · 2025Article
- Multi-active phlorotannins boost antimicrobial peptide LL-37 to promote periodontal tissue regeneration in diabetic periodontitis.Materials today. Bio · 2025Article
- Exploring the Inhibitory Potential of Sodium Alginate Against Digestive Enzymes Linked to Obesity and Type 2 Diabetes.Molecules (Basel, Switzerland) · 2025Article
- Revolutionizing Diabetes Care: The Role of Marine Bioactive Compounds and Microorganisms.Cell biochemistry and biophysics · 2025Review
- Investigation of the Pharmacodynamic Components ofInternational journal of molecular sciences · 2024Article
- Seaweeds as Nutraceutical Elements and Drugs for Diabetes Mellitus: Future Perspectives.Marine drugs · 2024Review
- Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition.Marine drugs · 2024Review
- Algae-Based Supplements Claiming Weight Loss Properties: Authenticity Control and Scientific-Based Evidence on Their Effectiveness.Marine drugs · 2024Article
- Study on the preparation and enzyme inhibitory activity of polyphenols from Sargassum pallidum.PloS one · 2024Article
- Algae-Derived Natural Products in Diabetes and Its Complications-Current Advances and Future Prospects.Life (Basel, Switzerland) · 2023Review
- Investigation of the Potential Phlorotannins and Mechanism of Six Brown Algae in Treating Type II Diabetes Mellitus Based on Biological Activity, UPLC-QE-MS/MS, and Network Pharmacology.Foods (Basel, Switzerland) · 2023Article
- Antioxidant and Antidiabetic Properties of Phlorotannins fromMolecules (Basel, Switzerland) · 2023Review
- Review
- A comprehensive review on algal nutraceuticals as prospective therapeutic agent for different diseases.3 Biotech · 2023Review
- Eckmaxol Isolated fromMarine drugs · 2022Article
- Call the Eckols: Present and Future Potential Cancer Therapies.Marine drugs · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a group of metabolic disorders characterized by hyperglycaemia, and predicted by the World Health Organization as the expected 7th leading cause of death in 2030. Diabetes mellitus type 2 (DMT2) comprises the majority of diabetic individuals around the world (90%-95%). Pathophysiologically, this disorder results from a deregulation of glucose homeostasis, worsened by overweight and by a sedentary lifestyle, culminating in life-threatening cardiovascular events. The currently available anti-diabetic drugs are not devoid of undesirable side effects, sometimes responsible for poor therapeutic compliance. This represents a challenge for contemporary medicine, and stimulates research focused on the development of safer and more efficient anti-diabetic therapies. Amongst the most promising sources of new bioactive molecules, seaweeds represent valuable, but still underexploited, biofactories for drug discovery and product development. In this review, the role of phlorotannins, a class of polyphenols exclusively produced by brown seaweeds, in the management of DMT2 will be discussed, focusing on various pharmacologically relevant mechanisms and targets, including pancreatic, hepatic and intestinal enzymes, glucose transport and metabolism, glucose-induced toxicity and β-cell cytoprotection, and considering numerous in vitro and in vivo surveys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.